« Return to News | Drug Sponsors

Pfizer backs out of pact with Biotica

Thursday, August 4, 2011 11:12 AM

Pfizer has returned the rights to a rapamycin analogue program it has been running to explore the potential of diseases such as multiple sclerosis and lupus to the UK's Biotica Technology, according to PharmaTimes.

The privately-owned group has regained full rights to the program which began after a deal was signed in 2006 with Wyeth (acquired by the US giant in October 2009). Since then, Pfizer has investigated these compounds in several diseases, "and in particular has extensively profiled candidate drugs in MS and systemic lupus erythematosus.”

Biotica says it intends to continue development in these indications but Pfizer is cutting back on its research activities and the project has been terminated. Mary Collins, chief scientific officer at the latter's immunology and autoimmunity research unit, said Pfizer had "enjoyed a productive collaboration with Biotica,” and the decision to return this program was made as part of its portfolio review process.

Edward Hodgkin, Biotica's chief executive, said, "Our compounds are supported by a strong data package generated by Pfizer, and show evidence of meaningful differentiation in diseases with significant unmet need."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.